Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05747443 | Multilevel Interventions to Increase Adherence to Lung Cancer Screening(Larch) | active not recruiting | N/A | 1,837 | Kaiser PermanenteOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05305365 |
| Study Assessing QBS72S For Treating Brain Metastases |
| active not recruiting |
| Phase 2 |
| 21 |
| Stanford UniversityOTHER |
| 1 |
| Dec 23, 2025 |
| clinicaltrials |
| NCT06125197 | Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 22 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02638090 | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06327074 | Testing the Engaged Approach to Lung Cancer Screening | active not recruiting | N/A | 40 | University of Colorado, DenverOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02201992 | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | active not recruiting | Phase 3 | 166 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 19, 2025 | clinicaltrials |
| NCT04863924 | Accelerating Lung Cancer Diagnosis Through Liquid Biopsy(ACCELERATE) | active not recruiting | — | 170 | University Health Network, TorontoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) | active not recruiting | Phase 3 | 563 | AmgenINDUSTRY | 29 | Dec 17, 2025 | clinicaltrials |
| NCT06397651 | A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life | active not recruiting | N/A | 146 | Complement Theory Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06461338 | Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study | active not recruiting | N/A | 60 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07274761 | Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. | active not recruiting | Phase 2 | 24 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07272356 | Evaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing Function | active not recruiting | N/A | 68 | Aurimas MacionisOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06530615 | Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer | active not recruiting | — | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07262671 | Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer(MPE-NSCLC) | active not recruiting | — | 100 | Fudan UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05103605 | Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations(POSITHES) | active not recruiting | — | 274 | AstraZenecaINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256002 | Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy | active not recruiting | — | 10,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT04823377 | Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.(PACT-01) | active not recruiting | N/A | 364 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT03143322 | Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases(STEREO-OS) | active not recruiting | N/A | 168 | UNICANCEROTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01754025 | INHERIT EGFR - Studying Germline EGFR Mutations(INHERIT) | active not recruiting | — | 121 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | active not recruiting | Phase 3 | 296 | PfizerINDUSTRY | 23 | Nov 25, 2025 | clinicaltrials |
| NCT05370469 | Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies(Lung001) | active not recruiting | N/A | 30 | University of VirginiaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors(MICA) | active not recruiting | Phase 1 | 440 | Cullinan Therapeutics Inc.INDUSTRY | 4 | Nov 24, 2025 | clinicaltrials |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy(ADRIATIC) | active not recruiting | Phase 3 | 730 | AstraZenecaINDUSTRY | 19 | Nov 21, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT07239544 | Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines | active not recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT05382052 | Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment(REAL-NADIM) | active not recruiting | — | 100 | Fundación GECPOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07237503 | THE EFFECT OF CALISTHENIC EXERCISES ON FATIGUE AND EXERCISE ATTITUDES IN PATIENTS WITH LUNG CANCER | active not recruiting | N/A | 33 | Hasan Kalyoncu UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04042701 | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 115 | Daiichi SankyoINDUSTRY | 4 | Nov 18, 2025 | clinicaltrials |
| NCT05690945 | A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 606 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy(ADAPTABLE) | active not recruiting | Phase 2 | 156 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05200481 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)(MP-ALK) | active not recruiting | Phase 2 | 110 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT00264602 | Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer | active not recruiting | Phase 1 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03672773 | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT03667820 | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | active not recruiting | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03707938 | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | active not recruiting | Phase 1 | 520 | AbbVieINDUSTRY | 10 | Oct 29, 2025 | clinicaltrials |
| NCT03334617 | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy(HUDSON) | active not recruiting | Phase 2 | 528 | AstraZenecaINDUSTRY | 8 | Oct 27, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 24, 2025source: clinicaltrials